Pediatric cancer and hematopoietic stem cell transplantation patients requiring renal replacement therapy: results of the retrospective nationwide AIEOP study

Leuk Lymphoma. 2022 Dec;63(12):2923-2930. doi: 10.1080/10428194.2022.2095628. Epub 2022 Jul 12.

Abstract

In children affected by malignancies and/or who received hematopoietic stem cell transplantation (HSCT), acute kidney injury (AKI) may occur causing a high mortality rate, despite the implementation of renal replacement therapy (RRT). We performed a nationwide, multicenter, retrospective, observational cohort study including consecutive patients between January 2010 and December 2019. One hundred and fourteen episodes of AKI requiring RRT coming from nine different Italian centers were included. The overall mortality rate was 61.4%. At the 3-month follow-up, the mortality rate was 47.4%. The mortality rate was higher in transplanted patients than those receiving chemotherapy. In particular, HSCT (p = 0.048) and invasive mechanical ventilation (p = 0.040) were significantly associated with death at three months after the end of dialysis in the multivariate analysis. Pediatric patients affected by malignancies complicated by AKI requiring RRT have a high mortality. The main factors associated to death are respiratory failure and having received HSCT.

Keywords: Pediatric oncology; acute kidney injury; dialysis; hematopoietic stem cell transplantation; pediatrics; renal replacement therapy.

Publication types

  • Observational Study
  • Multicenter Study

MeSH terms

  • Acute Kidney Injury* / epidemiology
  • Acute Kidney Injury* / etiology
  • Acute Kidney Injury* / therapy
  • Child
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Neoplasms* / complications
  • Neoplasms* / epidemiology
  • Neoplasms* / therapy
  • Renal Replacement Therapy / adverse effects
  • Retrospective Studies
  • Risk Factors